Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
04 Feb 2023
04 Feb 2023
Historique:
received:
26
09
2022
accepted:
21
01
2023
entrez:
4
2
2023
pubmed:
5
2
2023
medline:
5
2
2023
Statut:
epublish
Résumé
The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab (1 year vs 9 weeks) + chemotherapy. At a median follow-up of 8.7 years, patients who received AI had a significantly better DFS vs patients who received TAM or TAM-AI: 8-yr DFS 86.4 vs 79.7%, log-rank P = 0.013 (HR 1.52, 95% CI 1.09-2.11). In multivariate analysis, the type of endocrine therapy maintained a significant association with DFS (HR 1.64, 95% CI 1.07-2.52, p = 0.025 for TAM/TAM-AI vs AI). Among premenopausal patients aged ≤45 years, the use of GnRHa was associated with longer DFS: 8-yr DFS rate 85.2 vs 62.6% (log-rank p = 0.019, HR 0.41, 95% CI 0.19-0.88). In this post-hoc analysis of the ShortHER trial adjuvant treatment with AI was independently associated with improved DFS. Subgroup analysis in premenopausal patients suggests benefits with ovarian suppression.Trial registration: NCI ClinicalTrials.gov number: NCT00629278.
Identifiants
pubmed: 36739285
doi: 10.1038/s41523-023-00509-2
pii: 10.1038/s41523-023-00509-2
pmc: PMC9899279
doi:
Banques de données
ClinicalTrials.gov
['NCT00629278']
Types de publication
Journal Article
Langues
eng
Pagination
6Subventions
Organisme : Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Italian Medicines Agency)
ID : FARM62MC97
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : MFAG 2014
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 2019 Dec 10;37(35):3425-3435
pubmed: 31622131
Breast Cancer Res Treat. 2019 Aug;177(1):103-114
pubmed: 31134488
Ann Oncol. 2019 Mar 1;30(3):418-423
pubmed: 30657852
J Clin Oncol. 2018 Oct 1;36(28):2826-2835
pubmed: 30106636
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
Cancer Res. 2001 Dec 1;61(23):8452-8
pubmed: 11731427
Eur J Cancer. 2018 Feb;90:92-101
pubmed: 29274928
J Clin Oncol. 2005 Apr 10;23(11):2477-92
pubmed: 15767642
Oncologist. 2015 Sep;20(9):1001-10
pubmed: 26245675
J Clin Oncol. 2008 Mar 1;26(7):1059-65
pubmed: 18227529
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Eur J Cancer. 2017 Jul;79:129-138
pubmed: 28494403
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451
Lancet Oncol. 2022 Mar;23(3):382-392
pubmed: 35123662
J Clin Oncol. 2006 Jul 1;24(19):3019-25
pubmed: 16754938
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243
pubmed: 22513938
J Clin Oncol. 2021 Jan 1;39(1):79-89
pubmed: 32822287
Breast Cancer Res Treat. 1992;24(2):85-95
pubmed: 8095168
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Ann Oncol. 2018 Dec 1;29(12):2328-2333
pubmed: 30219886
Clin Breast Cancer. 2008 Oct;8(5):453-6
pubmed: 18952561
ESMO Open. 2021 Apr;6(2):100088
pubmed: 33735801
Clin Cancer Res. 2003 Mar;9(3):1039-46
pubmed: 12631604
Expert Rev Anticancer Ther. 2020 Dec;20(12):1011-1014
pubmed: 33021124
Nat Rev Clin Oncol. 2011 May;8(5):307-11
pubmed: 21151204
J Clin Oncol. 2017 Sep 10;35(26):3046-3054
pubmed: 28682681
Clin Cancer Res. 1998 Jan;4(1):7-12
pubmed: 9516946
Cancer Treat Rev. 2011 Apr;37(2):97-104
pubmed: 20594763
Ann Oncol. 2013 Oct;24 Suppl 6:vi7-23
pubmed: 23970019